Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in elderly adults to enhance vaccine immune response
ACTRN12611001241921Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of everolimus in immunosenescence (6 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability of low-dose or intermittently dosed everolimus and Change in influenza vaccine immune response. Started Jan 2012; status: completed.
02
Drugs
everolimus
03
Conditions
immunosenescence
Beyond the preview
Go deeper on ACTRN12611001241921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001241921.